1. Home
  2. LABT vs JAGX Comparison

LABT vs JAGX Comparison

Compare LABT & JAGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lakewood-Amedex Biotherapeutics Inc. Common Stock

LABT

Lakewood-Amedex Biotherapeutics Inc. Common Stock

N/A

Current Price

$0.84

Market Cap

2.2M

Sector

Health Care

ML Signal

N/A

Logo Jaguar Health Inc.

JAGX

Jaguar Health Inc.

HOLD

Current Price

$5.61

Market Cap

2.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LABT
JAGX
Founded
2006
2013
Country
United States
United States
Employees
N/A
47
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.2M
2.5M
IPO Year
2026
2014

Fundamental Metrics

Financial Performance
Metric
LABT
JAGX
Price
$0.84
$5.61
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
638.8K
★ 4.0M
Earning Date
11-18-2026
11-16-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 82.42
EPS
★ N/A
N/A
Revenue
N/A
★ $11,511,000.00
Revenue This Year
N/A
$77.78
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$0.82
$0.20
52 Week High
$6.85
$41.53

Technical Indicators

Market Signals
Indicator
LABT
JAGX
Relative Strength Index (RSI) 26.61 51.29
Support Level N/A $0.89
Resistance Level $2.13 $8.00
Average True Range (ATR) 0.21 4.77
MACD -0.10 -0.43
Stochastic Oscillator 1.78 13.02

Price Performance

Historical Comparison
LABT
JAGX

About LABT Lakewood-Amedex Biotherapeutics Inc. Common Stock

Lakewood-Amedex Biotherapeutics Inc is a clinical-stage biotechnology company developing a novel class of fast-acting, broad-spectrum antimicrobials - the Bisphosphocin class - to treat infectious diseases and reduce the threat posed by antibiotic-resistant bacterial strains, including MRSA, VRE, and others. The company's main product is Nu-3, a topically delivered antimicrobial gel in Phase 2 clinical trials for the treatment of mildly infected diabetic foot ulcers (iDFU). It is also advancing a portfolio of early-stage pipeline compounds developed from its Bisphosphocin platform targeting potential disease indications, including complicated urinary tract infection (cUTI) and pulmonary infections.

About JAGX Jaguar Health Inc.

Jaguar Health Inc is a commercial-stage pharmaceutical company developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for gastrointestinal disease states in humans and animals. The Company focuses on conditions associated with overactive bowel, including chronic debilitating diarrhea, urgency, and bowel incontinence. It operates through two segments: animal health, which develops and commercializes products for animals, and human health, with the human health segment generating the maximum revenue and focusing on products such as Mytesi, focusing on human products, specifically Mytesi, approved for symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.

Share on Social Networks: